Evidence map›Paper›PMID 33078692›Full record

ArticleJournal of feline medicine and surgery2021

Metastatic feline mammary cancer: prognostic factors, outcome and comparison of different treatment modalities - a retrospective multicentre study.

Gonçalo Petrucci, Joaquim Henriques, Hugo Gregório, Gonçalo Vicente, Justina Prada, Isabel Pires, Luís Lobo, Rui Medeiros, Felisbina Queiroga

Erratum issuedOpen access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of feline medicine and surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Review
  3. A One Health Perspective on Cancer: A Narrative Review.Medical sciences (Basel, Switzerland) · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Diagnostic Imaging Features of Mammary Gland Tumors in Dogs and Cats.Animals : an open access journal from MDPI · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Gonçalo PetrucciOnevet Veterinary Hospital of Porto, Porto, Portugal.ORCID 0000-0003-1751-2419
Joaquim HenriquesOnevet Berna Veterinary Hospital, Lisbon, Portugal.ORCID 0000-0002-2293-2277
Hugo GregórioVeterinary Hospital Centre, Porto, Portugal.
Gonçalo VicenteVeterinary School Hospital - Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal.
Justina PradaAnimal and Veterinary Research Centre (CECAV), University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.
Isabel PiresAnimal and Veterinary Research Centre (CECAV), University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.
Luís LoboOnevet Veterinary Hospital of Porto, Porto, Portugal.
Rui MedeirosMolecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal.
Felisbina QueirogaCentre for the Study of Animal Sciences, CECA-ICETA, University of Porto, Porto, Portugal.ORCID 0000-0001-6130-8381
University of Trás-os-Montes and Alto Douro · PTCUF Porto Hospital · PTInstituto Português de Oncologia Francisco Gentil · PTUniversidade do Porto · PTUniversity of Lisbon · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAlthough feline mammary carcinomas (FMCs) are highly metastatic, the literature and treatment options pertaining to advanced tumours are scarce. This study aimed to investigate the clinical outcome of metastatic FMC with or without adjuvant treatment.

methodsThe medical records of 73 cats with metastatic FMC (stage IV) were reviewed and included in this study. Metastatic disease was detected by distinct imaging techniques (radiography, ultrasound and CT) and confirmed by cytology and/or histopathology. Cats with adjuvant chemotherapy treatment (n = 34) were divided into three groups: group 1 (n = 9) cats receiving maximum tolerated dose chemotherapy; group 2 (n = 15) cats receiving metronomic chemotherapy; and group 3 (n = 10) cats treated with toceranib phosphate. The study endpoints were time to progression (TTP) and tumour-specific survival (TSS). Treatment-related toxicity was evaluated according to the Veterinary Co-operative Oncology Group's Common Terminology Criteria for Adverse Events version 1.1 (VCOG-CTCAE).

resultsOverall mean TTP and TSS were 23 and 44 days, respectively. Cats with clinical signs at the time of diagnosis had a lower TSS (14 days) than asymptomatic cats (128 days; CONCLUSIONS AND RELEVANCE: To the best of our knowledge, this study includes the highest number of patients with metastatic FMC assessed. Despite the overall poor prognosis, some cats survived >6 months, indicating that adjuvant treatment may be an option to consider in metastatic disease. More studies are warranted for better understanding and management of stage IV patients.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCat DiseasesAnimalsCatsChemotherapy, AdjuvantFemalePrognosisRetrospective StudiesAntineoplastic Agentsde novo metastaticmeloxicamMetastatic mammary tumourmetronomic chemotherapytoceranib phosphate

Identifiers

PMID33078692
PMCPMC10741299
OpenAlexW3093015584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.